《脊髓性肌萎缩症新生儿筛查专家共识（2023版）》解读
收稿日期: 2023-10-18
网络出版日期: 2023-12-04
基金资助
上海市自然科学基金资助项目(19ZR1476800)
季星 , 吴士文 . 《脊髓性肌萎缩症新生儿筛查专家共识（2023版）》解读[J]. 临床儿科杂志, 2023 , 41(12) : 942 -945 . DOI: 10.12372/jcp.2023.23e1006
| [1] | 中国研究型医院学会神经科学专业委员会, 中国出生缺陷干预救助基金会神经与肌肉疾病防控专项基金组织专家组. 脊髓性肌萎缩症新生儿筛查专家共识(2023版)[J]. 中华医学杂志, 2023, 103(27) : 2075-2081. |
| [2] | No authors listed. Committee opinion no. 691: carrier screening for genetic conditions[J]. Obstet Gynecol, 2017, 129(3): e41-e55. |
| [3] | Friedman JM, Cornel MC, Goldenberg AJ, et al. Global Alliance for Genomics and Health Regulatory and Ethics Working Group Paediatric Task Team. Genomic newborn screening: public health policy considerations and recommendations[J]. BMC Med Genomics, 2017, 10(1): 9. |
| [4] | 毛姗姗. 精准医学时代中国脊髓性肌萎缩症诊治发展之路[J]. 临床儿科杂志, 2022, 40(3): 165-169. |
| [5] | Finkel R, Farrar M, Servais L, et al. P212 RAINBOWFISH: Primary efficacy and safety data in risdiplam-treated infants with presymptomatic spinal muscular atrophy (SMA)[J]. Neuromuscular Diss, 2023, 33(Suppl 1): S87-S88. |
| [6] | Strauss KA, Farrar MA, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial[J]. Nat Med, 2022, 28(7): 1381-1389. |
| [7] | Strauss KA, Farrar MA, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial[J]. Nat Med, 2022, 28(7): 1390-1397. |
| [8] | Crawford TO, Swoboda KJ, De Vivo DC, et al. Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study[J]. Muscle Nerve, 2023, 68(2): 157-170. |
| [9] | Aragon-Gawinska K, Mouraux C, Dangouloff T. Spinal muscular atrophy treatment in patients identified by newborn screening-a systematic review[J]. Genes (Basel), 2023, 14(7): 1377. |
| [10] | 北京医学会医学遗传学分会, 北京罕见病诊疗与保障学会. 脊髓性肌萎缩症遗传学诊断专家共识[J]. 中华医学杂志, 2020, 100(40): 3130-3140. |
| [11] | Xu Y, Xiao B, Liu Y, et al. Identification of novel SMN1 subtle mutations using an allelic-specific RT-PCR[J]. Neuromuscul Disord, 2020, 30(3): 219-226. |
| [12] | Dai M, Xu Y, Sun Y, et al. Revealing diverse alternative splicing variants of the highly homologous SMN1 and SMN2 genes by targeted long-read sequencing[J]. Mol Genet Genomics, 2022, 297(4): 1039-1048. |
| [13] | Kariyawasam DST, Russell JS, Wiley V, et al. The implementation of newborn screening for spinal muscular atrophy: the Australian experience[J]. Genet Med, 2020, 22(3): 557-565. |
| [14] | Niri F, Nicholls J, Baptista Wyatt K, et al. Alberta spinal muscular atrophy newborn screening-results from year 1 pilot project[J]. Int J Neonatal Screen, 2023, 9(3): 42. |
| [15] | Kernohan KD, McMillan HJ, Yeh E, et al. Ontario newborn screening for spinal muscular atrophy: the first year[J]. Can J Neurol Sci, 2022, 49(6): 821-823. |
| [16] | Kimizu T, Ida S, Oki K, et al. Newborn screening for spinal muscular atrophy in Osaka -challenges in a Japanese pilot study[J]. Brain Dev, 2023, 45(7): 363-371. |
| [17] | Blaschek A, K?lbel H, Schwartz O, et al. Newborn screening for SMA-can a wait-and-see strategy be responsibly justified in patients with four SMN2 copies?[J]. J Neuromuscul Dis, 2022, 9(5): 597-605. |
| [18] | Bischof M, Lorenzi M, Lee J, et al. Matching-adjusted indirect treatment comparison of onasemnogene abepar-vovec and nusinersen for the treatment of sympto-matic patients with spinal muscular atrophy type 1[J]. Curr Med Res Opin, 2021, 37(10): 1719-1730. |
| [19] | Ribero VA, Daigl M, Martí Y, et al. How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison[J]. J Comp Eff Res, 2022, 11(5): 347-370. |
| [20] | Liao S, Bohn J, de Moor C, et al. A cautionary tale for indirect treatment comparisons: an example from infantile-onset spinal muscular atrophy[J]. Value Health, 2020: S709. |
| [21] | Lee BH, Deng S, Chiriboga CA, Kay DM, et al. Newborn screening for spinal muscular atrophy in new york state: clinical outcomes from the first 3 years[J]. Neurology, 2022, 99(14): e1527-e1537. |
/
| 〈 |
|
〉 |
沪公网安备 31011002000392号
